Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Slides:

Advertisements

Similar presentations

Cancer-Specific Inhibitory Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-β Against Choriocarcinoma in Xenografted.

Advertisements

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

IFN-γ antagonizes TGF-β in vivo.

FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.

IFN-γ activates the fibrinolytic system.

CD169+ macrophages play a critical role in mediating innate immune cell reorganization. CD169+ macrophages play a critical role in mediating innate immune.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

CCR2+ monocytes are a relevant source of type I IFN in response to Af.

Human cells produce type I and III IFNs upon Af stimulation.

Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells. Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

IL-10R-deficient macrophages secrete IL-23, inducing IL-22 secretion by ILC3 and TH17 cells. IL-10R-deficient macrophages secrete IL-23, inducing IL-22.

TCR signaling is required for exhausted-like TRM cell formation and maintenance. TCR signaling is required for exhausted-like TRM cell formation and maintenance.

BAP1 deficiency results in thymic atrophy and loss of thymocyte populations. BAP1 deficiency results in thymic atrophy and loss of thymocyte populations.

IFN-γ antagonizes TGF-β in vivo.

Neutrophil depletion ameliorates colitis in Cx3cr1cre:Il10rafl/fl BM chimeras. Neutrophil depletion ameliorates colitis in Cx3cr1cre:Il10rafl/fl BM chimeras.

Fig. 1 ZIKV RNA in blood and tissues.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

Fig. 3. Features of PH in KRasLA2 transgenic mice.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

IFN-γ activates the fibrinolytic system.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

Fig. 4. Genetically engineered PD-L1

Vaccine MN confer protective innate and adaptive immunity.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

RORα deficiency in Tregs results in exaggerated skin inflammation in response to EC sensitization. RORα deficiency in Tregs results in exaggerated skin.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

Derepression of co-silenced tumor suppressor genes by nanoparticle-loaded circular ssDNA reduces tumor malignancy by Jing Meng, Shuang Chen, Jing-xia Han,

by Ganesh V. Halade, Paul C. Norris, Vasundhara Kain, Charles N

Fig. 1 IDH3α expression is elevated in human-derived gliomas.

Fig. 4 PSMA PET/CT enables visualization of CD19-tPSMA(N9del) CAR T cell infiltration into local and metastatic tumors. PSMA PET/CT enables visualization.

Fig. 4 PD-L1 expression is found in the spleen and the BM of mice transplanted with JAK2V617F-transduced bone marrow. PD-L1 expression is found in the.

H19 was essential for cancer metastasis.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Nanoimmunotherapy production scale-up and evaluation in Apoe−/− mice

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Fig. 1 Deficient CD73 and CD39 expressions and extracellular adenosine concentration in BM of OVX animals. Deficient CD73 and CD39 expressions and extracellular.

Fig. 2 NDR2-deficient mice are more vulnerable to RNA viral infection.

Fig. 5. Vascularization of human liver seed grafts.

Targeting p53-dependent stem cell loss for intestinal chemoprotection

Chronic Treg reduction results in dermal fibrosis.

Tregs preferentially regulate TH2 cytokines in skin.

Fig. 1 Intra-amniotic delivery of CRISPR-Cas9 results in pulmonary gene editing. Intra-amniotic delivery of CRISPR-Cas9 results in pulmonary gene editing.

Patrolling monocytes control tumor metastasis to the lung

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 6 The combined therapeutic efficacy of N-pepABS and low dose of Dox on MDA-MB-231 xenografts. The combined therapeutic efficacy of N-pepABS and low.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

AV3 potentiates the effect of gemcitabine in the PDX model in mice

Fig. 5 In vivo autologous self-targeting efficacy of DR-KO tumor cells co-engineered with a secretable DRL and a suicide system. In vivo autologous self-targeting.

Fig. 7 BEL immune response.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

Fig. 1 TLR2 expression is induced during OIS.

Fig. 3 Minimal treatment of ETL decreases metastatic burden and prolongs survival in the 4T1 breast carcinoma model after tumor resection. Minimal treatment.

Fig. 1 Generation and characterization of MeV-based vaccine candidates for Lassa virus. Generation and characterization of MeV-based vaccine candidates.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

In vivo function of MeTro sealants using rat incision model of lungs

Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.

Fig. 5 Controlled tumor growth inhibition study of the self-assembled nanostructures. Controlled tumor growth inhibition study of the self-assembled nanostructures.

Presentation transcript:

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. (A) HeLa tumor volumes after CSSD-9 treatment at different doses. When tumors reached 100 to 200 mm3 in size, mice were treated with 10 and 20 μg of CSSD-9 via I.T. or I.V. injection. Tumor sizes were measured every 3 days, and tumor volumes were calculated. (B) SiHa, A549, and HepG2 tumor images and growth curves after CSSD-9 treatment by I.V. and I.T. injection. (C) Visible metastatic nodules on the surface of lungs in the control and CSSD-9–treated mice (top). Representative figures of hematoxylin and eosin (H&E) staining were performed on serial sections of metastatic tumors in the lungs. Scale bars, 50 μm. (D) Number of metastatic lung nodules was quantified in the control and CSSD-9 treatment groups. (E) miR-9 expression in the control and CSSD-9 groups was detected by qRT-PCR after lysis of tumor tissues and RNA extraction. (F) mRNA expression of KLF17, CDH1, and LASS2 in control and CSSD-9 treatment groups was detected by qRT-PCR. (G) Expression of KLF17, CDH1, and LASS2 was confirmed with Western blot analysis after lysis of tumor tissues. (H) Left: In vivo fluorescence imaging of a BALB/c nude mouse that received I.V. injection of A549-GFP cells and treated with CSSD-9 by I.V. injection. Right: CTCs were detected by flow cytometry. (I) Infiltration of CD8+ T cell (CD3+CD8+) and IFN-γ+ cell percentage in the tumor tissues after CSSD-9 treatment by I.T. or I.V. injection. (J) Percentages of MDSCs in tumor tissues, bone marrow (BM), and spleen after CSSD-9 treatment. All data are represented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001. Jing Meng et al., Sci Transl Med 2018;10:eaao6321 Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works